Latest news with #Stockholm
Yahoo
5 minutes ago
- Business
- Yahoo
Sandvik: Interim report second quarter 2025
STOCKHOLM, July 16, 2025 /PRNewswire/ -- Order intake SEK 32,206 million (32,354) Order intake, at fixed exchange rates, increased by 10% Revenues SEK 29,700 million (31,419) Revenue growth, at fixed exchange rates increased by 4% Adjusted EBITA SEK 5,629 million (6,149) Adjusted EBITA margin 19.0% (19.6) Adjusted EBIT SEK 5,194 million (5,688) Adjusted EBIT margin 17.5% (18.1) Adjusted profit before tax SEK 4,855 million (5,124) Profit for the period SEK 3,216 million (3,462) Adjusted profit for the period SEK 3,713 million (3,897) Earnings per share, diluted SEK 2.56 (2.76) Adjusted earnings per share, diluted SEK 2.96 (3.10) Free operating cash flow SEK 5,090 million (4,198) Additional information may be obtained from Sandvik Investor Relations, phone +46 70 782 63 74 (Louise Tjeder). A webcast and conference call will be held on July 16, 2025, at 1:00 PM CEST. Information is available at Stockholm, July 16, 2025Sandvik Aktiebolag (publ) Stefan WidingPresident and CEO This information is information that Sandvik AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at about 11:30 AM CEST on July 16, 2025. This information was brought to you by Cision The following files are available for download: Interim Report Q2 2025 View original content: SOURCE Sandvik
Yahoo
5 minutes ago
- Business
- Yahoo
Fingerprint Cards AB (publ) updates on upcoming reverse share split
As previously announced on July 8, 2025, the upcoming reverse share split could not be carried out due to unforeseen technical issues beyond Fingerprint Cards AB's (publ) ('FPC' or the 'Company') control and the Company withdrew the resolution for the record date planned to be held on July 11, 2025. The issues were related to an inaccurate provided estimate of shares required to round up each shareholder's holdings. The actual number of shares needed proved to be significantly higher, which if the reverse share split had been conducted, would have resulted in considerable cost to the Company in providing the rounding shares. To mitigate this and facilitate a reverse share split, the Board of Directors have decided to propose the Extraordinary General Meeting a revised intended technique for the reverse share split and instead use a so-called 'rounding down-method', meaning that for those shareholders who on the record date for the aggregation do not hold a number of Class B shares corresponding to a whole number of new ordinary shares (after the aggregation has been completed), excess Class B shares will be transferred to the Company's ownership on the record date for the aggregation. Excess Class B shares will then be sold by the Company or a securities institution appointed by the Company, whereby eligible shareholders will receive their share of the sale proceeds. Under the revised reverse split process, shareholders who do not hold an exact multiple of 2,000 shares will receive cash compensation for any excess shares. This ensures no economic loss to Class B shareholders.1 The reverse share split would mean that the Company's Class A and Class B shares will be subject to a reverse split at a ratio of 1:2,000, resulting in one (1) share for every two thousand (2,000) existing shares of the same class, with all class-specific rights and characteristics remaining unchanged. After the reverse share split has been completed, the number of shares and votes in the Company, based on the current number of outstanding shares, will decrease from 15,175,375,766 shares (7,875,000 A-shares and 15,167,500,766 B-shares) and 15,246,250,766 votes to 7,587,687 shares (3,937 A-shares and 7,583,750 B-shares) and 7,623,120 votes. The reverse share split is proposed by the Board of FPC considering the Company's operational and financial progress in recent years, which enables continued growth initiatives, and to achieve an appropriate number of shares for the Company. The Company intends to carry out the reverse share split during the third quarter of 2025. Notice of the Extraordinary General Meeting will be published in a separate press release. For further information, please contact: Adam Philpott, CEO Investor Relations: +46(0)10-172 00 10, investrel@ Press: +46(0)10-172 00 20, press@ About FPC Fingerprint Cards AB (FPC) is a global biometrics leader, offering intelligent edge to cloud biometrics. We envision a secure, seamless world where you are the key to everything. Our solutions – trusted by enterprises, fintechs, and OEMs – power hundreds of millions of products, enabling billions of secure, convenient authentications daily across devices, cards, and digital platforms. From consumer electronics to cybersecurity and enterprise, our cloud-based identity management platforms support multiple biometric modalities, including fingerprints, iris, facial, and more. With improved security and user experience, we are driving the world to passwordless. Discover more at our website and follow us on LinkedIn and X for the latest updates. FPC is listed on Nasdaq Stockholm (FING B).1 Note: Shareholders holding fewer than two thousand (2,000) shares at the record date for the reverse share split will have their holdings rounded down to zero (0) and hence no longer remain shareholders in FPC. Attachment 250716 - Update on reverse splitError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
5 minutes ago
- Business
- Yahoo
AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, RUSSIAN FEDERATION, BELARUS, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES. ADDITIONAL RESTRICTIONS ARE APPLICABLE, PLEASE SEE "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE. STOCKHOLM, SE / / July 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB ("AlzeCure" or the "Company") has received additional subscription commitments of SEK 7 million from a group of qualified investors in the Company's ongoing rights issue announced on June 16, 2025 (the "Rights Issue"). Should the issue be oversubscribed, the Company intends to utilize the remaining portion of the Over-Allotment Option, following the previously announced additional subscription commitment, to accommodate these subscriptions to the greatest extent possible. In addition to previously entered subscription commitments, a group of qualified investors have committed to subscribe for shares amounting to approximately SEK 7 million, corresponding to about 14 percent of the Rights Issue. The subscription commitments are based on the same terms as for other investors, i.e. no remuneration. In the event the issue is oversubscribed and the allocation under these additional subscription commitments cannot be fully allocated, the Company intends to utilize the remaining portion of the Over-Allotment Option of around SEK 5 million to accommodate theses subscription to the greatest extent possible in accordance with the principle that allocation under the overallotment option shall primarily be made to strategic and/or qualified investors. Following these additional subscription commitments, the total amount of subscription commitments entered into amounts to approximately SEK 32 million, corresponding to around 66 percent of the total amount of the Rights Issue of approximately SEK 48.5 million, with an over-allotment option of SEK 10 million. "At AlzeCure Pharma, we are very pleased with the interest and support we are seeing for the share issue, both from existing major shareholders and new investors. This demonstrates confidence in the share issue and the plans it is intended to finance, which primarily include preparations for the upcoming Phase 2 study in Alzheimer's patients with NeuroRestore ACD856 - a project for which we have secured funding from the European Innovation Council. We are very proud of this support, which can also be seen as a validation of the project," says Martin Jönsson, CEO of AlzeCure. Additional subscription commitments: Investor Subscription commitment, SEK Jan Poulsen 2,000,000 Niklas Estensson 1,000,000 Christian Månsson 1,000,000 Rose-Marie Karlsson 1,000,000 Alexander Schoeneck 1,000,000 AV Linbo Invest AB 660,000 Johan Wiklund 308,000 TOTAL 6,968,000 The subscription period for the share issue runs through July 22. More information is available at: Advisors AlzeCure has engaged Zonda Partners AB and Synch Advokat AB as financial and legal advisors, respectively, in connection with the Rights Issue. In connection with the additional subscription commitment addressed in this press release, Corpura Fondkommission AB has also acted as joint bookrunner. Important information The information in this press release does not contain or constitute an offer to acquire, subscribe for, or otherwise trade in shares, subscription warrants, or other securities in AlzeCure. No action has been taken, and no actions will be taken, to permit a public offering in any jurisdiction other than Sweden. Any invitation to eligible persons to subscribe for shares in AlzeCure will only be made through the supplementary Information Document published by AlzeCure on 7 July 2025. The information in this press release may not be announced, published, or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States, Belarus, Russia, South Korea, Switzerland, or any other jurisdiction where such action would be unlawful, subject to legal restrictions, or would require actions other than those required under Swedish law. Any failure to comply with these restrictions may constitute a violation of applicable securities laws. For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit Attachments AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the ongoing Rights Issue SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire
Yahoo
an hour ago
- Health
- Yahoo
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
STOCKHOLM, July 16, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's disease which was co-developed by Eisai and BioArctic, has received the 9th Bioindustry Award from the Japan Bioindustry Association (JBA). Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease. These discoveries are the basis for lecanemab, an antibody treatment developed in collaboration with the Japanese company Eisai. By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear amyloid-beta from the brain, thereby altering the course of the disease. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region. The information was released for public disclosure, through the agency of the contact person below, on July 16, 2025, at 9:30 a.m. CET. For further information, please contact: Oskar Bosson, VP Communications and IRE-mail: +46 70 410 71 80 About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit This information was brought to you by Cision The following files are available for download: The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
5 hours ago
- Business
- Wall Street Journal
Handelsbanken Net Profit Misses Forecasts After Income Falls
STOCKHOLM—Svenska Handelsbanken's SHB.B -2.50%decrease; red down pointing triangle second-quarter net profit fell, missing analysts' expectations, as lower costs failed to offset a decline in income. The Swedish bank on Wednesday reported net profit of 5.49 billion Swedish kronor ($564.3 million), down from 6.79 billion kronor a year earlier. Analysts polled by FactSet had forecast 5.92 billion kronor.
